ã€ãã«ãžã§ã³(iverjohn) 3mg/6mg/12mg 人éåãã€ãã«ã¡ã¯ãã³
â»ããã±ãŒãžãªãã¥ãŒã¢ã«ãªã©ã®çç±ã«ããå®éã®ååãšã¯ãã¶ã€ã³ãç°ãªãå ŽåããããŸãã
â»ããã±ãŒãžãèª¬ææžãä»å±ããç°¡æå
è£
ã»PTPã·ãŒãã®ã¿ã§ã®é
éãšãªãå ŽåãããããŸããããäºæ¿ãã ããã
åãæåã®å»è¬å(å çºè¬ã»ãžã§ããªãã¯)
ãã®è¬ãšåãæåã®å»è¬åã¯èŠã€ãããŸããã§ããããææ°ã§ããã以äžã®ãã¿ã³ããé¡äŒŒè¬ããæ¢ããã ããã
ã€ãã«ãžã§ã³ã®è©³çް
ã€ãã«ãžã§ã³ãšã¯
- å»è¬åå
- ã€ãã«ãžã§ã³(Iverjohn)
- ã¡ãŒã«ãŒ
- ãžã§ã³ãªãŒã»ãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãº(JohnLee Pharmaceuticals)
- æå¹æå
- ã€ãã«ã¡ã¯ãã³(Ivermectin)
- 广ã»å¹èœ
- ç³ç·è«ãç¥ç¬ãæ¯å è«çãªã©ã®å¯çè«æ²»ç
- å€åœ¢
- ã¿ãã¬ãã(tablet)
- æ°åã³ããã®æ²»çè¬ãšããŠæ³šç® æå¹æåã®ã€ãã«ã¡ã¯ãã³ã¯æ°åã³ãããŠã€ã«ã¹ã®åæçç¶ã®æ²»çã»äºé²ã«å¹æããããšããŠäžççã«æ³šç®ãéããŠããŸãããå®ããšããŠè³Œå ¥ãããæ¹ãã
- ç¥ç¬ã®ç¹å¹è¬ãšã㊠ç¥ç¬ã«å¯ŸããŠéåžžã«åŒ·åãªå¹æãçºæ®ãå¯äœçšããªã¹ã¯ãäœãå¯ãããã®å ç«åŒ±è ãé«éœ¢è ã«å¯ŸããŠãæ¯èŒçå®å šã«äœ¿çšã§ããŸãã
- é ãã®æ¹åã«ã广ãã ããããããæ»æ» ããã广ããããæ ¢æ§çãªé ã(é¡ã®èµ€ã¿ãå¹ãåºç©)ãçŽ æãªã©ã®çç¶ãæ¹åããŸãã
ã€ãã«ãžã§ã³ã¯ç³ç·è«ãç¥ç¬ãæ¯å
è«çãªã©ç¹å®ã®å¯çè«ã«ãã£ãŠåŒãèµ·ããããææçãæ²»çããæå¯çè«è¬ã§ãã
æå¹æåã®ã€ãã«ã¡ã¯ãã³ã«ã¯è«ã®ç¥çµãç现èã«äœçšã麻çºã»æ»æ»
ããã广ãããããçç¶ã®ç·©åãæåŸ
ã§ããŸãã
åç©çšã€ãã«ã¡ã¯ãã³è£œå€ãšã¯ç°ãªãããã¡ãã¯äººéãå®å šã«äœ¿çšã§ããããšã確ç«ãããŠããå»è¬åã§ããåç©çšã§ã¯ãããŸããã®ã§ã泚æãã ããã
ãŸããè¿å¹Žã§ã¯æ°åã³ãããŠã€ã«ã¹(COVID-19)æ²»çè¬ãšããŠã®ç ç©¶ãé²ãã§ããŸãã
èšåºè©Šéšã®çµæã§ã¯ãŠã€ã«ã¹ãæžå°ããã广ã確èªããããªã©å®éšçãªæ®µéãªããæåŸ
ãéããæåãšãªã£ãŠããŸãã
广ã»å¹èœ
å¯çè«
ã€ãã«ãžã§ã³ã®æå¹æåã€ãã«ã¡ã¯ãã³ãå¯çè«ã«å¯ŸããŠå¹æãçŸãä»çµã¿ã¯ãŸã å ·äœçã«ã¯æããã«ãªã£ãŠããŸããããè«ã®ç¥çµãç现èã«äœçšã麻çºã»æ»æ» ããããšèããããŠããŸãã
æ°åã³ãããŠã€ã«ã¹(COVID-19)
ç 究段éã§ã¯ãããŸãããæ°åã³ãããŠã€ã«ã¹ã«å¯Ÿããæ²»çè¬ãšããŠãæ€èšãããŠããŸãã
æ°åã³ãããŠã€ã«ã¹ãçºç ããããã«ã¯ãŸã人éã®çްèã«ææããå¿ èŠãããã现èã«äŸµå ¥ãããšãŠã€ã«ã¹ã¯çްèå ã§èªèº«ã®ã³ããŒã倧éã«äœæãäœäžãžåºãŸã£ãŠããä»çµã¿ã§ãã
äžæ¹ã§ãã®ãŠã€ã«ã¹ã«ã¯ææã«å¯Ÿããäœã®æµæåã匱ããäœçšããããããææãæªåããå¯èœæ§ããããŸãã
ã€ãã«ã¡ã¯ãã³ã«ã¯ãŠã€ã«ã¹ãçŽ°èæ žå
ã«å
¥ãã®ããããã¯ããäœçšããããšãèããããŠããŠãææãšæãŠã€ã«ã¹åå¿äœäžã®äž¡æ¹ãé²ããå¯èœæ§ããããŸãã
ããã«ããææã»çºç
ããŠãäœã¯éåžžéãææçãšéããããã«ãªããã®ã§ãã
äžäŸã§ã¯ãããŸããã補è¬äŒç€ŸICONã®èšåºè©Šéšçµæã§ã¯ã€ãã«ã¡ã¯ãã³çŸ€ã®å šæ»äº¡ç(15%)ã¯éåžžã®æ²»ç矀(25.2%)ãšæ¯èŒããŠææã«äœãã£ããšå ±åããããªã©æå¹æ§ãæåŸ ãããŠããŸãã
æ°åã³ãããŠã€ã«ã¹(COVID-19)
æ°åã³ãããŠã€ã«ã¹ã¯ã€ã³ããŒãã³(Importin)ãšåŒã°ãã茞éã¿ã³ãã¯è³ªã«çµåããæ žèåè€åäœ(NPC)ãéããŠçŽ°èæ žã«åã蟌ãŸããããšã§å¢æ®ãææãä¿é²ããããšèããããŠããŸãã
ã€ãã«ã¡ã¯ãã³ã«ã¯ã€ã³ããŒãã³ãšãŠã€ã«ã¹ã®çµåã劚ããäœçšããããšãããææãæå¶ããå¯èœæ§ããããŸãã
ãŠã€ã«ã¹ã¯åäœã§ã¯çŽ°èæ žå ã«å ¥ãããšãã§ããªããããçç¶ã®æªåãæãŠã€ã«ã¹åå¿ã®äœäžãé²ã广ãæåŸ ãããŠããŸãã
é£²ã¿æ¹ã»äœ¿ãæ¹
ã€ãã«ãžã§ã³ã¯çç¶ã«åãããçšéãã³ããäžæ¯ã®æ°Žã§æçšããŠãã ããã
æçšã®ã¿ã€ãã³ã°ã¯é£äºã®1æé以äžåãããã¯2æé以äžåŸã®ç©ºè
¹ã«æçšããããã«ããŠãã ããã
ãããå
ç«åã匱ãå Žå(ç
æ°ãç¹å®ã®è¬ã®äœ¿çšã«ãã£ãŠåŒãèµ·ãããã)ã¯ã€ãã«ã¡ã¯ãã³ãè€æ°åæçšããå¿
èŠããããããããŸããã
å
ç«åãåŒ±ãæ¹ãæçšã®éã¯å»åž«ã®æç€ºã«åŸã£ãŠãã ããã
äžè¬çãªæäººã®çšéã¯ä»¥äžã®ãšããã§ãã
å¯çè«
- æ²³å·ç²ç®ç(ãªã³ã³ã»ã«ã«ç)
0.15mg/kgã§èšç®ããéã«æãé©å(è¿ã)ãªçšéã®é å€ã12ã¶æã«1åã®ã¿æçšããŠãã ããã - ç³ç·è«ç
0.2mg/kgã§èšç®ããéã«æãé©å(è¿ã)ãªçšéã®é å€ã2é±éã«1åæçšããŠãã ããã - åè«çã»ç®è幌è«ç§»è¡çã»ãã£ã©ãªã¢ç
0.2mg/kgã1åæçšã - ç¥ç¬
0.2mg/kgã1åæçšã2é±éã§ç¹°ãè¿ãã - åè«ç
0.2mg/kgã1åæçšã
æ°åã³ãããŠã€ã«ã¹ã«å¯ŸããŠã®å®ããããçšéã¯ãããŸããããæ²»éšãªã©ã§çšããããäŸã¯ä»¥äžã®éãã§ãã
æ°åã³ãããŠã€ã«ã¹(COVID-19)
- åéç ç©¶æã®æ²»éš
(軜床)0.2mg/kgã忥ã«1åæçš - FLCCCäºé²æçšæ³ãããã³ã«
(äºé²)0.2mg/kgã忥ãš48æéåŸã«1åæçšããã®åŸ2é±éããš
(軜床)ã€ãã«ã¡ã¯ãã³0.2mg/kgã1æ¥1åãå埩ãããŸã§(ãããã¯2ïœ5æ¥)
詳现ïŒhttps://covid19criticalcare.com/i-mask-prophylaxis-treatment-protocol/i-mask-protocol-translations/
è¬ã¯ãªãã¹ã湿æ°ãç±ãæ¥å ãé¿ããŠåžžæž©ä¿åããŠãã ããããŸãã誀飲ãé¿ããããåäŸãããããããå Žåã«ã¯ä¿ç®¡å Žæã«çްå¿ã®æ³šæãæã£ãŠãã ããã
å¯äœçš
ã€ãã«ãžã§ã³ã¯æå¹æåã€ãã«ã¡ã¯ãã³ã«ããå¯äœçšãåŒãèµ·ããå ŽåããããŸãã
以äžã¯äžè¬çãªå¯äœçšã§ç¹ã«å»åž«ã®æ²»çãå¿
èŠãšããŸããããçšåºŠãæ°ã«ãªãå Žåã¯å»åž«ã«çžè«ããŠãã ããã
ç¹ã«ããŸãã倱ç¥ã«ã€ããŠã¯æªæã䌎ãå Žåãããããã座ã£ããæšªã«ãªã£ããããŠããç¶æ ããã¯ãã£ãããšèµ·ãäžããããã«ããããéæ®µã®äžãäžãã«ã泚æããŠãã ããã
äž»ãªå¯äœçš
- é çãçèç
- ç®ãŸã
- åãæ°ãäžç¢
- 軜床ã®çºç¹
ãã ããæçšåŸã«ä»¥äžã®å¯äœçšãçŸããå Žåã¯ãã ã¡ã«äœ¿çšãäžæ¢ãå»åž«ã®æ²»çãåããŠãã ããã
æ²»çãå¿ èŠãªçç¶
- ç®ã®çã¿ãå è¡ãç®ã®è «ããèŠåé害
- é床ã®çºç¹ãããã¿ãè¿ã䌎ãçºç¹
- é¯ä¹±ã粟ç¥ç¶æ ã®å€åã平衡æèŠéå®³ãæ©è¡é害
- çºç±ããªã³ãè ºã®è «ããèçãé¢ç¯çãæè¶³ã®ããã¿
- é »èãåŒåžå°é£
- æå°¿ãæäŸ¿ãå¶åŸ¡ã§ããªã
- éŠãèäžã®çã¿ããããã
- æ°ã倱ããããªãµãã€ãæ
ç¹ã«ä»¥äžã®å Žåã¯ç·æ¥ã®æ²»çãå¿ èŠãšãªããŸãã
ã¢ã¬ã«ã®ãŒåå¿ã®åŸŽå
- ãããŸç¹
- åŒåžå°é£
- é¡ãåãèãåã®è «ã
ã€ãã«ãžã§ã³ã¯æçšã«ãã以äžã®å¯äœçšãåŒãèµ·ããå¯èœæ§ããããŸãã
ãããã®å¯äœçšã¯äœãè¬ã«é å¿ããã«ã€ããŠæ¶ããå¯èœæ§ãããéåžžã¯å»åž«ã®èšºå¯ãå¿
èŠãšããŸããã
æ²³å·ç²ç®ç(ãªã³ã³ã»ã«ã«ç)ã®æ²»çæã®ã¿
äžè¬çãªå¯äœçš
- çºç±ãããã¿ãçºç¹
- é¢ç¯ãçèã®çã¿
- éŠãããã®äžãéŒ åŸéšã®çã¿ãšãªã³ãè ºã®å§ç
- é »æ
ããŸãäžè¬çã§ãªãå¯äœçš
- é ç
- é¡ãæãè ãè¶³ããŸãã¯èã®è «ã
çããå¯äœçš
- è¥äœãŸãã¯åº§äœããç«ã¡äžãã£ããšãã®ãµãã€ã
ç³ç·è«çã®æ²»çæã®ã¿
ããŸãäžè¬çã§ãªãå¯äœçš
- äžç¢
- ç®ãŸã
- çºç¹ã»ããã¿
çããå¯äœçš
- 飿¬²äžæ¯
- éããæºãã身éã
- ç æ°
ãã ããæçšäžã«æ¬¡ã®ããããã®çç¶ãçºçããå Žåã¯ãã ã¡ã«å»åž«ã®æ²»çãåããŠãã ããã
æ²³å·ç²ç®ç(ãªã³ã³ã»ã«ã«ç)ã®æ²»çæã®ã¿
ããŸãäžè¬çã§ãªãå¯äœçš
- çŒããŸã¶ãã®åºæ¿ãçã¿ãçºèµ€ãè «ã
çžäºäœçš
飲é ã¯ã€ãã«ã¡ã¯ãã³ã®ç¹å®ã®å¯äœçšãå¢å¹ ããå¯èœæ§ããããã䜵çšãé¿ããŠãã ããã
ãã®ä»ã«ããã€ãã«ã¡ã¯ãã³ãšçžäºäœçšãåŒãèµ·ããæåã¯åŠæ¹è¬ãåžè²©è¬ãããã¿ãã³ãããŒãã«è³ããŸã§æ°å€ãã®æåãæããããŸãã
ãããã®çžäºäœçšã¯ãããŸã§ä»£è¡šçãªãã®ã®ã¿ã§å
šãŠã«ã€ããŠåæããŠããããã§ã¯ãããŸããããæ³šæãã ããã
çŠå¿ã»æ³šæç¹
ã€ãã«ãžã§ã³ã®æå¹æåã€ãã«ã¡ã¯ãã³ã«å¯ŸããŠã¢ã¬ã«ã®ãŒãããå Žåãäœéã15kgæªæºã®åäŸã«ã¯è¬ãæçšããªãã§ãã ããã
ãŸãããã以äžã«è©²åœããå Žåã¯å»åž«ã«çžè«ãå®å šæ§ã確èªããäžã§è¬ãæçšããŠãã ããã
å»åž«ã«ç¢ºèªãå¿ èŠãªçŸç
- èã»è çŸæ£
- çãHIVããšã€ãºãªã©å ç«ç³»ã匱ããå¯èœæ§ã®ããç æ°ã«ããã£ãŠãã
ã€ãã«ã¡ã¯ãã³ã¯èå ã«å®³ãåãŒããã©ããäžæãªãããåŠåš äžã»åŠåš äºå®ã®æ¹ã¯å»åž«ã«çžè«ã®äžã§æçšããŠãã ããã
ãã®ä»ãæ¯ä¹³ã«ç§»è¡ããå¯èœæ§ãããæä¹³äžã®èµ€ã¡ããã«å®³ãåãŒãå¯èœæ§ããããããèµ€ã¡ããã«æä¹³ããŠããå Žåãåæ§ã§ãã
ãããã質å
- Q.æ°åã³ãããŠã€ã«ã¹ã«å¹ãã®ã¯æ¬åœã§ããïŒ
- A.ããããå®éšçµæã§ãŠã€ã«ã¹ãå€§å¹ ã«æžå°ããã广ã確èªãããŠããŸãããå®é𿮵éã®ãã广ã«ã€ããŠä¿èšŒãããã®ã§ã¯ãããŸããã
- Q.人éçšã®è¬ãæ¢ããŠããã®ã§ãããããããå®¶ççšã§ã¯ãªãã§ããïŒ
- A.ãã¡ãã®ã€ãã«ãžã§ã³ã¯äººéçšã®åŠæ¹å»è¬åã»ã¹ããã¡ã¯ããŒã«ã®ãžã§ããªãã¯ã«ãããå»è¬åã§ããåç©çšã€ãã«ã¡ã¯ãã³è£œå€ã§ã¯ããããŸããã